3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
6
Phase 2
2
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
81
Myeloid
41
Lymphoid
16
Gastrointestinal
6
Plasma cell
5
Thoracic
4
Genitourinary
4
CNS
3
Breast
3
Tumor-Agnostic
2
Dermatologic
2
Classical hematology
2
Sarcoma
1
Head & Neck
1
Gynecologic
1
Conditions
Uveal Melanoma
1
Melanoma
1
Head and Neck Neoplasms
1
Interventions
pembrolizumab
65
Cisplatin
42
Cetuximab
36
Radiotherapy
28
Nivolumab
26
Paclitaxel
22
Carboplatin
22
Docetaxel
20
durvalumab
14
Radiotherapy, Intensity-Modulated
12
Fluorouracil
12
Cyclophosphamide
11
tremelimumab
9
Gemcitabine
9
Ipilimumab
8
fludarabine
7
avelumab
7
Erlotinib Hydrochloride
7
toripalimab
6
epacadostat
6
cemiplimab
6
Radiosurgery
6
Interleukin-2
6
Capecitabine
6
Bevacizumab
6
spartalizumab
5
Celecoxib
5
zalutumumab
4
tislelizumab
4
fludarabine phosphate
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Azacitidine
×
Head & Neck
×
Clear all
NCT04729543
2023-12-04
MC2TCR
Erasmus Medical Center
Phase 1/2
Recruiting
20 enrolled